secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273272
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q3 2025 R&D expenses $39.8M; rese-cel BLA submission targeted for 2027
--------------------------------------------------------------------------------

- R&D expenses of $39.8M in Q3 2025, up from $26.3M a year ago; cash $159.9M as of Sep 30, 2025.
- Myositis registrational cohort (14 patients) set to begin enrollment by year-end 2025; BLA submission planned for 2027.
- FDA alignment on registrational cohort designs for SSc and SLE trials expected by year-end 2025.
- EMA granted PRIME designation for rese-cel in myositis; FDA granted RMAT for SLE/LN and Fast Track for gMG.
- Steve Gavel appointed Chief Commercial Officer; led CARVYKTI launch at Legend Biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/0001193125-25-273272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312525273272/caba-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer